Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
Completed · Phase 2 · Has a placebo group
Conditions studied: Breast Cancer
In brief
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of letrozole may stop cancer from forming or coming back in postmenopausal women who are at increased risk for breast cancer due to high breast density. PURPOSE: This randomized phase II trial is studying how well letrozole works in preventing breast cancer in postmenopausal women who are at increased risk for breast cancer due to high breast density.
Key facts
- Study ID
- NCT00238316
- Run by
- NCIC Clinical Trials Group
- People needed
- 68
- Starts
- 2000-12-05
- Expected to finish
- 2009-02-10
- Last updated by the study team
- 2020-04-02
Who can join
Age: any, up to 120. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Tom Baker Cancer Centre - Calgary — Calgary, Alberta, Canada
- Nova Scotia Cancer Centre — Halifax, Nova Scotia, Canada
- Hamilton Osteoporosis Diagnostic Services — Hamilton, Ontario, Canada
- Ottawa Hospital Regional Cancer Centre - General Campus — Ottawa, Ontario, Canada
- St. Catharines General Hospital at Niagara Health System — St. Catharines, Ontario, Canada
- Toronto Sunnybrook Regional Cancer Centre at Sunnybrook Health Sciences Centre — Toronto, Ontario, Canada
- Princess Margaret Hospital — Toronto, Ontario, Canada
- Hotel Dieu de Montreal — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.